Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2143568 | Lung Cancer | 2008 | 7 Pages |
Abstract
To compare the overall survival (OS) of patients with advanced non-small cell lung (NSCLC) treated with either docetaxel plus gemcitabine or single-agent docetaxel. Chemotherapy-naive patients with advanced/metastatic NSCLC were randomly assigned to receive either DG [n = 157; gemcitabine 1100 mg/m2 on days 1 and 8], docetaxel 75 mg/m2 on day 8 or D [n = 155; docetaxel 100 mg/m2 on day 1] every 3 weeks. A total of 312 patients were evaluable for toxicity and response. A predefined interim intention-to-treat analysis showed significantly longer median OS (p = 0.037) in favor of the DG regimen (9.4 months versus 8.3 months for DG and D regimens, respectively), resulting in the premature termination of the study. The DG regimen was also associated with a significantly higher response rate compared to D (26.8% versus 11.6%, p < 0.001). TTP were 3.5 and 2.3 months for the DG and D regimen, respectively (p = 0.054). Although there were two treatment-related deaths in the DG arm, the toxicity profiles of the two regimens were comparable. The DG regimen was associated with a significantly better quality of life. The efficacy of the docetaxel plus gemcitabine combination is superior to single-agent docetaxel in chemonaive patients with advanced NSCLC.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Vassilis Georgoulias, Nikolaos Androulakis, Athanasios Kotsakis, Dora Hatzidaki, Kostas Syrigos, Aris Polyzos, Athina Agelidou, Ioannis Varthalitis, Nikoalos Ziras, Maria Agelidou, Vassilis Chandrinos, Ioannis Boukovinas, Alexandra Geroyianni,